Genetically Modified MSCs for Targeted Regeneration: Balancing Efficacy, Biosafety, and GMP Standardization
Cells · 03.08.2026 · 15 (15) · 1406
DOI: 10.3390/cells15151406 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 03.08.2026. Verfasst von Kristina V Kitaeva und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Regeneration, Regenerative Medicine, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tatarstan Academy of Sciences.
Abstract (Originalsprache)
Mesenchymal stromal cells (MSCs) are a versatile platform for regenerative medicine and gene delivery because they combine multipotency, immunoregulatory activity, and injury-directed trafficking. Translation is nevertheless limited by donor- and tissue-dependent heterogeneity, variable biodistribution, and engineering-related risks. This review evaluates genetically modified MSCs as medicinal products rather than as a general MSC class. We compare self-inactivating lentiviral (SIN-LV) transduction, which provides efficient and durable expression and has limited early clinical experience, with targeted genome editing, which can define the integration locus and copy number but remains constrained by variable precise knock-in efficiency, off-target and double-strand-break-associated effects, manufacturing cost, and the absence of long-term clinical safety data. We integrate preclinical and clinical evidence with GMP-compatible manufacturing, potency testing, genomic surveillance, and release criteria. Particular attention is given to safe-harbor integration and B2M/CIITA-based hypoimmunogenic designs as strategies to reduce engineering-related batch variability and HLA-dependent donor variability. Together, these developments support a transition from empirically optimized MSC preparations toward molecularly defined cellular medicines with predefined genotype, expression, potency, and safety attributes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
- Division of Medical and Biological Sciences, Tatarstan Academy of Sciences, 420111 Kazan, Russia.
- Center for Advanced Technologies, Academy of Sciences of the Republic of Uzbekistan, Tashkent 100174, Uzbekistan.
ORCID-Profile: Kristina V Kitaeva, Ivan Y Filin, Albert A Rizvanov, Shahlo Turdikulova, Mirakbar Yakubov, Oksana Charishnikova, Valeriya V Solovyeva
Förderung
- Tatarstan Academy of Sciences
Zitieren
APA
Kitaeva, K. V., Filin, I. Y., Rizvanov, A. A., Turdikulova, S., Yakubov, M., Charishnikova, O., & Solovyeva, V. V. (2026). Genetically Modified MSCs for Targeted Regeneration: Balancing Efficacy, Biosafety, and GMP Standardization. Cells, 15(15), 1406. https://doi.org/10.3390/cells15151406
Vancouver
Kitaeva KV, Filin IY, Rizvanov AA, Turdikulova S, Yakubov M, Charishnikova O, et al. Genetically Modified MSCs for Targeted Regeneration: Balancing Efficacy, Biosafety, and GMP Standardization. Cells. 2026;15(15):1406. doi:10.3390/cells15151406
BibTeX
@article{Kitaeva2026,
author = {Kitaeva, Kristina V and Filin, Ivan Y and Rizvanov, Albert A and Turdikulova, Shahlo and Yakubov, Mirakbar and Charishnikova, Oksana and Solovyeva, Valeriya V},
title = {Genetically Modified MSCs for Targeted Regeneration: Balancing Efficacy, Biosafety, and GMP Standardization},
journal = {Cells},
year = {2026},
volume = {15},
number = {15},
pages = {1406},
doi = {10.3390/cells15151406}
}
EUVIMED